PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease

J Cardiovasc Transl Res. 2021 Apr;14(2):238-245. doi: 10.1007/s12265-020-10050-3. Epub 2020 Jun 23.

Abstract

It is essential to study the factors associated with the evolution of aortic stenosis progression (ASP) to develop therapies that could reduce it. We studied 283 patients 6 months after acute coronary syndrome (ACS). ASP was defined as an increase in the maximum aortic velocity of at least 0.5 m/s between the echocardiogram performed during ACS hospitalization and the last one recorded in the electronic medical registry. The median follow-up was 72.4 months. Twenty patients (7%) had ASP. A multivariate binary logistic regression analysis was performed showing that PCSK9 plasma levels (OR, 0.668 CI (0.457-0.977); p = 0.038), HS-CRP (OR, 1.034 CI (1.005-1.063); p = 0.022), the presence of dyslipidemia (OR, 4.622 CI (1.285-16.618); p = 0.019), the history of PAD (OR, 9.453 CI (1.703-52.452); p = 0.010), and GFR (OR, 0.962 CI (0.939-0.986); p = 0.002) were independent predicting factors of ASP. In patients with ischemic heart disease, low plasma levels of PCSK9 and elevated levels of HS-CRP are independent predictors of ASP.

Keywords: Coronary artery disease; Valvular heart disease.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aortic Valve Stenosis / blood*
  • Aortic Valve Stenosis / diagnostic imaging
  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Coronary Artery Disease / blood*
  • Coronary Artery Disease / diagnosis
  • Disease Progression
  • Echocardiography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Proprotein Convertase 9 / blood*
  • Risk Assessment
  • Risk Factors

Substances

  • Biomarkers
  • C-Reactive Protein
  • PCSK9 protein, human
  • Proprotein Convertase 9